HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Oncology
FDA Approval
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
FDA
May 15, 2026
Oncology
Sys. Review
Case report and literature review on oxaliplatin and tegafur for AEG with intramural metastasis
A rare cancer spread inside the esophagus wall needs careful treatment plans for older adults
This case report and literature review examines a 77-year-old male with adenocarcinoma of the esophagogastric junction and esophageal intram…
A doctor reviewed a rare case where cancer spread inside the esophagus wall. This condition often means the disease is already in the body. …
Frontiers
May 11, 2026
Dermatology
Sys. Review
Review of case report suggests multimodal therapy potential for unresectable intraductal papillary mucinous neoplasms of the bile duct
At-a-Glance
This review of a case report describes two patients with unresectable intraductal papillary mucinous neoplasms of the bile duct treated with…
A new three-drug combination shrank a rare bile duct tumor in one patient and stopped another from growing, offering hope for a cancer with …
Frontiers
May 8, 2026
Oncology
Meta-analysis
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors
New analysis shows pucotenlimab improves outcomes for several solid tumor types
This meta-analysis evaluated pucotenlimab (HX008) in patients with gastric, gastroesophageal junction, triple-negative breast cancer, melano…
A new analysis of pucotenlimab shows significantly improved outcomes versus control for patients with gastric cancer, triple-negative breast…
May 1, 2026
Oncology
Phase I
S-1 plus oxaliplatin consolidation shows low toxicity in stage II/III lower rectal cancer patients
First study reports SOX consolidation for lower rectal cancer
This Phase I study enrolled 12 patients with stage II/III lower rectal adenocarcinoma.
A small early trial found SOX chemotherapy was safe after radiation for lower rectal cancer, with surgery completed on time for all patients…
May 1, 2026
Oncology
RCT
Neoadjuvant mFOLFOXIRI plus bevacizumab reduces peritoneal tumor burden in colorectal cancer patients
Chemo before surgery may reduce tumor burden in colorectal cancer patients
This phase II randomized controlled trial evaluated 53 patients with resectable peritoneal metastasis of colorectal cancer.
A trial suggests chemo before surgery might lower tumor markers for colorectal cancer patients with spread to the abdomen.
Apr 28, 2026
Oncology
Cohort
Machine learning model predicted FOLFIRINOX dose modifications in pancreatic ductal adenocarcinoma cohort
Most patients on strong pancreatic cancer chemo needed a dose change
This cohort study included 514 patients with pancreatic ductal adenocarcinoma treated at UCSF oncology clinics.
Over 60% of patients with pancreatic cancer needed a dose adjustment during treatment with FOLFIRINOX at UCSF clinics.
medRxiv
Apr 28, 2026
Oncology
RCT
Tumor debulking plus chemotherapy did not improve overall survival in multiorgan metastatic colorectal cancer patients
Surgery Doesn’t Extend Life for Advanced Colon Cancer
This randomized clinical trial enrolled 382 adult patients with multiorgan metastatic colorectal cancer across 27 hospitals in the Netherlan…
This large study shows that removing tumors in advanced colon cancer doesn’t help people live longer.
JAMA
Apr 23, 2026
Oncology
Sys. Review
Case report describes sintilimab-associated toxic epidermal necrolysis in gastric carcinoma patient
Rare Skin Reaction Follows Successful Stomach Cancer Therapy
This case report details a patient with gastric carcinoma developing delayed-onset toxic epidermal necrolysis during neoadjuvant sintilimab …
A new case shows a common stomach cancer drug can cause dangerous skin reactions even after surgery.
Frontiers
Apr 22, 2026
Hematology
Sys. Review
Case report and literature review of ENKTL presenting with ocular symptoms and treated with GemOx
A Rare Eye Symptom Led Doctors Down the Wrong Path for Months
This case report and literature review describes a single patient with extranodal natural killer/T cell lymphoma presenting with ocular symp…
Double vision and sinus scans that looked clean hid a rare lymphoma that stole a man's sight after months of wrong treatments.
Frontiers
Apr 18, 2026
Oncology
RCT
Subcutaneous PEG-rhG-CSF reduced grade ≥3 neutropenia and CIN in GI cancer patients receiving oral chemotherapy
New Shot Cuts Severe Low White Blood Cell Risk
This prospective, single-center, open-label, exploratory, non-randomized controlled study evaluated subcutaneous PEG-rhG-CSF in 43 gastroint…
A simple shot given before chemotherapy could keep your body's infection-fighting cells strong when taking oral cancer pills.
Frontiers
Apr 16, 2026
Geriatrics & Aging
Phase II
Adapted-dose FOLFIRINOX assessed for safety and early efficacy in elderly patients with metastatic pancreatic cancer
New Drug Combo Helps Older Pancreatic Cancer Patients Live Longer
This Phase II multicentric study evaluated adapted-dose FOLFIRINOX in 72 elderly patients (aged 70 years or older) with metastatic pancreati…
A new drug mix helps older pancreatic cancer patients live longer while keeping them active, provided doctors check specific genes first to …
CT.gov
Apr 16, 2026